Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Foteini Strimenopoulou"'
Autor:
Guillemette de la Borderie, Damien Chimits, Babak Boroojerdi, Melissa Brock, Petra W. Duda, Fiona Grimson, Paul Mahoney, Foteini Strimenopoulou, Gary Cutter, Inmaculada Aban, Susanna Brauner, Malin Petersson, James F. Howard, Nathan Bennett
Publikováno v:
Therapeutic Advances in Neurological Disorders, Vol 17 (2024)
Background: Clinical efficacy of zilucoplan has been demonstrated in a 12-week, placebo-controlled, phase III study in patients with acetylcholine receptor autoantibody-positive generalised myasthenia gravis (gMG). However, placebo-controlled zilucop
Externí odkaz:
https://doaj.org/article/5edf8e359a4044d7bccfc5460aa5f32c
Autor:
Gary Burgess, Malcolm Boyce, Margaret Jones, Lars Larsson, Mark J. Main, Frazer Morgan, Peter Phillips, Alison Scrimgeour, Foteini Strimenopoulou, Pavan Vajjah, Miren Zamacona, Roger Palframan
Publikováno v:
EBioMedicine, Vol 35, Iss , Pp 67-75 (2018)
Background: Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-
Externí odkaz:
https://doaj.org/article/4112209b44a549208dede8f273b97447
Autor:
Jingjing Ye, Vickie Zhang, Foteini Strimenopoulou, Yihua Zhao, Haitao Pan, Mayadah Shabbout, Margaret Gamalo
Publikováno v:
Journal of Biopharmaceutical Statistics. :1-15
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ed634765a7991c89bcd86aba0bf2fd9
https://doi.org/10.1080/10543406.2023.2170407
https://doi.org/10.1080/10543406.2023.2170407
Autor:
Stevan Shaw, Sophie Glatt, Dominique Baeten, Foteini Strimenopoulou, Iain B. McInnes, Georg Schett, Robert Landewé, Mark I L Watling, Lucian Ionescu, Peter C. Taylor
Publikováno v:
Annals of the Rheumatic Diseases
Annals of the rheumatic diseases, 78(8), 1033-1040. BMJ Publishing Group
Annals of the rheumatic diseases, 78(8), 1033-1040. BMJ Publishing Group
ObjectiveEvaluate the efficacy and safety of dual neutralisation of interleukin (IL)-17A and IL-17F with bimekizumab, a monoclonal IgG1 antibody, in addition to certolizumab pegol (CZP) in patients with rheumatoid arthritis (RA) and inadequate respon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c543268a73c0c31ab241918f48f10b53
https://doi.org/10.1136/annrheumdis-2018-214943
https://doi.org/10.1136/annrheumdis-2018-214943
Autor:
Mamta Joshi, Moira Thomson, Emma L. Smith, Yuk-Fun Liu, Mark Peakman, Nikolaos Fountoulakis, Jake Powrie, Sefina Arif, Foteini Strimenopoulou
Publikováno v:
Diabetes. 67
Background: Peptide immunotherapy (PIT) aims to modulate immune responses to specific antigens in order to restore immune tolerance. Recently, we reported outcomes of a phase 1b study of PIT at type 1 diabetes onset, showing safety, tolerability and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6e666f45b873b1a8635648c1312a00d0
https://doi.org/10.2337/db18-1733-p
https://doi.org/10.2337/db18-1733-p
Autor:
Frazer Giles Morgan, Mark Jonathan Main, Peter Phillips, Pavan Vajjah, Roger Palframan, Malcolm Boyce, Foteini Strimenopoulou, Miren Zamacona, Lars Larsson, Margaret Jones, Gary Burgess, Alison Scrimgeour
Publikováno v:
EBioMedicine. 35
Background Interleukin-13 (IL-13) is a key mediator of T-helper-cell-type-2 (Th-2)-driven asthma, the inhibition of which may improve treatment outcomes. We examined the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of VR942, a dry-p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99a94c824823103326f3fbd6734ffdf0
https://pubmed.ncbi.nlm.nih.gov/30120079
https://pubmed.ncbi.nlm.nih.gov/30120079
Autor:
Pavan Vajjah, Dominique Baeten, Sophie Glatt, Lucian Ionescu, Stevan Shaw, Foteini Strimenopoulou, Serghei Popa
Publikováno v:
Annals of the Rheumatic Diseases. 75:95.3-96
Background Bimekizumab (UCB4940) is a potent and selective monoclonal antibody inhibiting the activity of both IL-17A and IL-17F, which are key pro-inflammatory cytokines overexpressed in skin lesions of patients with psoriasis.1 Blocking both IL-17A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::65e80d033f60705b8e6843f7b4a982d0
https://doi.org/10.1136/annrheumdis-2016-eular.2952
https://doi.org/10.1136/annrheumdis-2016-eular.2952
Publikováno v:
Statistical Applications in Genetics and Molecular Biology. 7
We construct a diagnostic predictor for patient disease status based on a single data set of mass spectra of serum samples together with the binary case-control response. The model is logistic regression with Bernoulli log-likelihood augmented either
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::05d79e16ef53a150650c33008e1d8263
https://doi.org/10.2202/1544-6115.1359
https://doi.org/10.2202/1544-6115.1359
Autor:
Terry Baker, Serghei Popa, Ash Maroof, Lucian Ionescu, Mark I L Watling, Sophie Glatt, Pavan Vajjah, Pierre Miossec, Dominique Baeten, Stevan Shaw, Meryn Griffiths, Foteini Strimenopoulou, Ruth Oliver, Nataliya Yeremenko, Alastair D. G. Lawson
Publikováno v:
Annals of the rheumatic diseases, 77(4), 523-532. BMJ Publishing Group
Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases
ObjectiveInterleukin (IL)-17A has emerged as pivotal in driving tissue pathology in immune-mediated inflammatory diseases. The role of IL-17F, sharing 50% sequence homology and overlapping biological function, remains less clear. We hypothesised that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f37ec189d9f186862b8ffac77dcdbf2b